Carmat Is A Medtech Company Focused On Developing Bioprosthetic Artificial Hearts To Treat Advanced Heart Failureits Flagship Productthe Aesonatotal Artificial Heartis Designed To Replace The Ventricles And Mimic Natural Heart Functionthe Device Is Ce Marked In Europe And Is Currently Undergoing Clinical Trials In The U Sto Validate Its Safety And Efficacy Carmat Provides Mechanical Circulatory Support For Patients In Need Of A Bridge To Transplantthe Company Conducts Clinical Studiesincluding The Eficas Trial In France And The U Searly Feasibility Studyto Gather Data On Its Productswith A Commitment To Improving Patient Quality Of Lifecarmat Aims To Be A Leading Alternative To Heart Transplantsaddressing The Global Shortage Of Donor Organsthe Company Collaborates With Healthcare Providersregulatory Bodiesand Payor Entities To Enhance Its Offerings And Expand Its Reach
